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ABSTRACT Complement-stimulated granulocytes adhere to
and induce significant 51Cr release from endothelial cells in vitro.
Platelets were stimulated to undergo release, and these release
products significantly enhanced granulocyte-endothelial cell ad-
herence and granulocyte-induced 5tCr release from endothelial
cells. Platelet serotonin appeared to mediate these phenomena
because serotonin antagonists blocked both the enhanced endo-
thelial adherence and 5tCr release. In addition, added serotonin
mimicked the effect seen with the stimulated platelets upon gran-
ulocyte-endothelial cell adherence and cytotoxicity completely.
This enhancement appeared to be due to serotonin effects upon
both the granulocyte and endothelial cells. These data suggest that
a released platelet constituent might modulate in vivo granulo-
cyte-endothelial cell interactions in clinical disorders.
Endothelial injury, followed by subendothelial cell prolifera-
tion, is thought to play a prominent role in virtually all models
of vascular injury and atherogenesis (1). Speculation on the
etiology of the proliferative response has centered upon the role
of platelet-derived "growth factors" (2); however, the mecha-
nisms for initiating endothelial cell damage have been given less
attention. Recent studies from our laboratory have focused upon
the damaging effects on the vascular endothelium of granulo-
cytes (polymorphonuclear leukocytes) that have been stimu-
lated by various immunologic stimuli, particularly activated
complement components (3). These studies were fostered by
our interest in the acute pulmonary dysfunction that occurs
early in hemodialysis (4). Abnormalities in pulmonary dynamics
that hemodialyzed patients manifest also may be reproduced
in laboratory animals by reinfusing them with autologous plasma
that had been allowed to contact hemodialyzer membranes (5,
6); pulmonary microvascular damage and associated pulmonary
interstitial edema were evident in these animals (5, 6).
By visualizing the microvasculature of rat mesenteries
through laser intravital microscopy, Hammerschmidt et al (7)
observed that infused complement, particularly C5a, first pro-
moted granulocyte adhesion to endothelium, followed shortly
thereafter by plasma leak into interstitial tissues (7). A potential
mechanism for this vascular damage was suggested by in vitro
studies of cultured endothelial cells (8). When exposed to gran-
ulocytes and a source of activated complement, labeled en-
dothelial cells released chromium, and this release was largely
inhibited by superoxide dismutase and catalase. It appeared
likely, therefore, that the complement-stimulated production
of reactive oxygen species by granulocytes underlies the en-
dothelial cell alteration, a surmise validated by recent studies
of others (9).
Because platelets and their products have been suggested as
important effectors in atherogenesis-possibly in proliferative
response of injured vessels-we undertook the present in vitro
studies to determine their possible role in complement-me-
diated vascular injury. This report indicates that platelets, al-
though ineffectual alone, exacerbate the release of radioactive
label from cultured endothelial cells exposed to complement-
coated particles with granulocytes. One mediator of this am-
plification appears to be the platelet constituent, serotonin,
which we find enhances the adhesion of complement-stimu-
lated granulocytes to their target endothelial cells. The results,
reported preliminarily elsewhere (10), suggest that platelets
may play an endothelium-damaging role in addition to their
previously suspected effects of inciting vascular wall proliferation.
METHODS AND MATERIALS
Preparation of Endothelial Cells. Endothelial cells were
grown in culture in microtiter wells by our previously reported
modification of established methods (8, 11, 12). Cells were cul-
tured under 95% air/5% CO2 at 370C in medium 199 containing
20% calf serum (GIBCO); they were used =5 days after expla-
nation, just prior to reaching confluence, and were identified
as endothelium by their reaction with rabbit antisera to human
Factor VIII antigen (13) (Boehringer Corporation, New York,
NY). In selected studies, the cultured cells were incubated with
sodium arachidonate (100 uM) or thrombin (1 unit/ml) for 5
min; the supernatant fluid was then aspirated and assayed for
the stable prostacyclin metabolite 6-keto-prostaglandin F1. by
using a radioimmunoassay (New England Nuclear).
Blood Cell Preparation. Granulocytes were harvested from
heparin-treated (6-8 unit/ml) volunteer peripheral blood by
using standard techniques of dextran sedimentation, hypotonic
lysis, and Ficoll/Hypaque sedimentation (8, 14). The enriched
granulocytes were washed and resuspended (final concentra-
tion, 1 x 107 cells per ml) in Hanks' balanced salt solution
(Microbiological Associates, Walkersville, MD) containing
0.5% human albumin. The purified granulocytes contained 5-
10% mononuclear cells and < 1 x 10 platelets per ml. Platelets
were harvested from citrated (0.36%) peripheral blood by cen-
trifugation (400 g for 5 min) to yield platelet-rich plasma (PRP).
"Purified platelets" were obtained by centrifugation of PRP
(1,400 x g for 10 min), with resuspension in Ca/Mg-free Hanks'
Abbreviation: PRP, platelet-rich plasma.
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balanced salt solution (final concentration, 5 X 108 platelets per
ml).
Determination of 51Cr Release. Endothelial cells were la-
beled by addition of 5 uCi (1 Ci = 3.7 x 10'° becquerels)
Na251CrO4 (New England Nuclear) to serum-free medium 16
hr before planned experiments (8, 11). In each experiment,
controls for spontaneous 51Cr release consisted of labeled cells
from the same microtiter plate treated identically but without
addition of immune reactants. Specific release refers to that
obtained by subtracting the release from cultures containing
unstimulated neutrophils from those that contained stimulated
neutrophils. The reactants included, where appropriate: (i) 5
X 106 neutrophils; (ii) PRP or "purified platelets" (2 x 108);
(iii) zymosan (Nutritional Biochemicals, Cleveland, OH) opson-
ized in fresh serum (30 min at 37TC) and resuspended to 5 mg/
ml in Ca/Mg-free Hanks' balanced salt solution; (iv) various
concentrations of serotonin (5-hydroxytryptamine; Sigma); (v)
100 ,uM methysergide maleate (a gift of Sandoz Pharmaceuti-
cal); or (vi) 1 ,uM imipramine hydrochloride (Sigma). The re-
action wells, which contained 3 x 105 labeled endothelial
cells and specific reactants in a final volume of 1.5 ml, were
incubated at 37TC for 30 min and washed three times with
Hanks' balanced salt solution containing 0.5% albumin. The
washes were pooled for counting. The still-attached endothelial
cells were mechanically removed from the wells and separately
counted. For calculation of 51Cr release, care was taken to sed-
iment and recombine with the endothelial cell fraction any in-
tact endothelial cells removed during washing; >90% of chro-
mium was released from these cells during three freeze/thaw
cycles. Our previous experiments (8, 11) had demonstrated that
resting granulocytes or activated serum complement, when
added separately, do not induce significant 51Cr leak; this was
confirmed in the present study.
The validity of using 51Cr release as a marker of endothelial
cell alteration was strengthened by using another cell label,
[I4C]thymidine, which was preincorporated into endothelial
cells for 72 hr prior to the experiment. In both situations, the
released supernatant radioactivity (51Cr or 14C) was expressed
as a percentage of the total cell plus supernatant fluid radio-
activity recovered from each well.
Granulocyte Adherence Assay. Purified granulocytes (5 x
106) were placed atop either endothelial cells or "naked" plastic
microtiter tissue culture wells (201 mm2, Costar, Cambridge,
MA) in the presence of Hanks' balanced salt solution with al-
bumin (0.5%) or in this same buffer containing 15% (vol/vol)
heated or zymosan-activated serum. After incubation for 30 min
at 37°C, nonadherent cells were removed by vigorous aspiration
and two additional washes. Adherent granulocytes were then
removed with trypsin/EDTA; microscopic inspection revealed
recovery of all granulocytes. The myeloperoxidase activity in
both the pooled aspirates and adherent fractions was then de-
termined by standard techniques (11, 15); the percentage ad-
herence was calculated by dividing the myeloperoxidase activity
of the adherent fraction by the total activity recoverable in each
well. Recovery of myeloperoxidase activity was close to 100%
of that predicted, and endothelial cells contained no demon-
strable myeloperoxidase activity.
Granulocyte Function Studies. Granulocyte superoxide an-
ion (O-) was determined by the capacity of o- to reduce fer-
ricytochrome c, as previously described by Goldstein et al (16).
Release of H202 by purified granulocytes was assayed by using
the decrease in fluorescence intensity of scopoletin due to its
peroxidase-mediated oxidation by H202 (11, 17). cAMP levels
were determined by radioimmunoassay (New England Nuclear)
with purified granulocytes after their exposure to serotonin.
After incubation at 370C for various periods of time, the reac-
tions were terminated by placing the tubes in boiling water (5
min), and extracting the cells by freezing and thawing in dis-
tilled water. Protein was measured by the method of Lowry et
al. (18). Neutrophil hexose monophosphate-shunt activity was
determined in granulocytes incubated with 1 ACi of D-[1-
'4C]glucose (New England Nuclear) as described by De-
Chatelet et al. (19).
RESULTS
Platelets Amplify Granulocyte-Mediated Release of En-
dothelial Radiolabel. In confirmation of our earlier studies (8,
11), endothelial cells exposed to granulocytes that are stimu-
lated by activated complement-either as zymosan-activated
plasma (not shown) or as zymosan particles opsonized by serum
complement components (shown in Table 1)-released signif-
icant amounts of Na251CrO4 (Table 1, line 2). To determine the
possible role of circulating blood cells other than granulocytes,
we exposed 1 x 107 cells from whole "buffy coat," rather than
density-separated granulocytes, to opsonized zymosan and then
added this stimulated, mixed cell population to the labeled en-
dothelial cells; "buffy coat" cells induced roughly a 2-fold in-
crease (P < 0.01) in specific 51Cr release from the endothelial
cells compared to that noted with more purified granulocytes
(Table 1, line 3). The augmented specific 51Cr release probably
reflects the presence of platelets in the "buffy coat" because
addition ofPRP in quantities adjusted to the same approximate
platelet radioactivity as that in "buffy coats" produced a similar
amplification of endothelial cell 51Cr release (Table 1, line 4).
Table 1. Platelets augment granulocyte-mediated 61Cr release
from endothelial cells
51Cr release
n % P
SAZ* 5 1.4 ± 0.6 -
PMN + SAZ 10 5.5 ± 0.8 -
"Buffy coat" cells + SAZ 3 9.7 ± 1.2 <0.05
PMN + plateletst + SAZ 8 10.0 ± 1.0 <0.01
Plateletst + SAZ 3 1.9 ± 1.6 -
PMN + platelet supernatants
fraction + SAZ 3 11.9 ± 0.8 <0.01
PMN + platelet pellet fractions
+ SAZ 3 5.1 ± 1.1 -
PMN + aspirin-treated platelets§
+ SAZ 3 4.6 ± 1.4 -
SAZ, serum-activated zymosan; PMN, granulocyte(s). Results are
expressed as the mean percentage release ± SEM (30 min) of 51Cr
minus the spontaneous release from untreated cells in parallel wells.
Each experiment utilized as an internal control the spontaneous 51Cr
release from cells grown from the same pool of umbilical cords. Mean
spontaneous release was 4.4% per 30 min. Previous studies indicated
that granulocytes alone cause no significant 51Cr release (8, 11); in-
dividual studies were run in triplicate.
* +Zymosan (5.0 mg/ml) was added to fresh serum and incubated for
30 min; 0.15 ml was then added to the reaction wells.
t PRP (0.4 ml; 2 x 108 platelets) was added prior to addition of the zy-
mosan particles. Release of labeled serotonin from platelets ranged
between 35% and 57% with opsonized zymosan stimulation of plate-
let release.
t Platelet release supernatant fraction was prepared by incubating
PRP with zymosan particles. After 30 min, the platelets and zymosan
were sedimented (20,000 x g for 15 min), and the supernatant frac-
tion or the pellet (resuspended in an equivalent volume of zymosan-
activated serum) was then added to the endothelial cells.
§ Aspirin-treated platelets were obtained from normal volunteers who
had taken 600 mg of aspirin 12 and 24 hr prior to phlebotomy. These
platelets did not undergo aggregation in the presence of opsonized
zymosan (5.0 mg/ml). P values represent comparison with values in
line 2 and were performed by utilizing a standard two-tailed t test.
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However, complement-triggered platelets alone-that is, with-
out added granulocytes but in the presence of activated com-
plement-induced no significant 5"Cr release (Table 1, line 5).
"Purified platelets" (PRP further enriched in platelets by re-
centrifugation) amplified endothelial 51Cr release to a similar
degree (results not shown). Furthermore, the concentration of
added platelets was critical, with no significant amplification of
51Cr release seen with <1 X 108 platelets and only a slightly
increased release (12.1 ± 1.3%) when the platelet concentration
was increased 3-fold (6 X 108).
In ancillary studies, we noted that the platelet amplification
phenomenon was only discernable if complement-opsonized
particles, but not fluid-phase complement (e.g., plasma after
removal of zymosan particles), were present in the system.
Others have demonstrated that particulate- but not fluid-phase
activated complement causes the release reaction in human
platelets (20-22). We confirmed this observation; release ofser-
otonin from labeled platelets engendered by particulate acti-
vated complement ranged between 35% and 57% in five sep-
arate experiments, whereas there was virtually no release when
fluid-phase complement was used to stimulate platelets labeled
with 14C serotonin. Therefore, we postulated that a secreted
platelet product was the amplifier of granulocyte-mediated,
endothelial 51Cr release. Indeed, centrifuged supernatants of
platelets that had undergone release by exposure to opsonized
zymosan particles potently amplified endothelial 51Cr release
(Table 1, line 6), whereas the "spent" platelet pellet was without
effect (Table 1, line 7). Moreover, platelets either obtained from
donors taking aspirin (Table 1, line -8) or from a patient with
storage pool disease (not shown) were incapable of amplifying
51Cr release from endothelial cells.
Identification of the Platelet-Derived Amplifier. Two sep-
arate lines of evidence indicate that serotonin (5-hydroxytryp-
tamine) may be at least one platelet-derived amplifier of gran-
ulocyte-mediated 51Cr release. When imipramine, an inhibitor
of serotonin uptake, or methysergide, a serotonin competitive
inhibitor, were added to platelet release products, these then
failed to amplify granulocyte-induced 51Cr release (Fig. 1 Left).
Moreover, serotonin itself amplified granulocyte-mediated re-
lease from endothelial cells. This amplified release also could
be blocked by including the same concentrations ofimipramine
or methysergide (Fig. 1 Right) in the mixture of serotonin and
stimulated granulocytes. However, serotonin in the absence of
stimulated granulocytes did not cause endothelial injury (<2%
specific 51Cr release, n = 5).
Serotonin amplified endothelial chromium release induced
by activated granulocytes in a dose-dependent fashion; clearly
detectable amplification was observed at 0.1 ,AM, and maximal
effects were noted between 0.5 and 1 ,M (Fig. 2). Confirmatory
results were obtained with [t4C]thymidine as the endothelial
cell label: unstimulated-granulocytes provoked 1.6 ± 0.5% re-
lease of this label (as trichloroacetic acid-precipitable radioac-
tivity), which increased to 6.5 ± 1.1% with addition of opson-
ized zymosan and further increased to 15.5 ± 1.6% in the
presence of serotonin (1 /.LM).
Mechanism of Serotonin Amplification. Our previous stud-
ies showed that granulocyte-mediated damage to endothelial
cells requires close apposition ofeffector and target cells-prob-
ably because the reactive oxygen species generated by comple-
mented-stimulated granulocytes are rapidly dissipated (8, 11).
Serotonin significantly enhanced adhesion of granulocytes
(whether complement-stimulated or not) to endothelium but
not to plastic (Table 2), providing one plausible mechanism for
its augmentation of endothelial cytotoxicity. The augmentation
of granulocyte adherence induced by serotonin was prevented
by methysergide or imipramine (not shown). These inhibitors
did not retard granulocyte adherence when serotonin was not
present. In addition, a modest stimulation ofgranulocyte hexose
monophosphate-shunt activity by serotonin (Table 2) might con-
tribute also to its potentiating effects because increments in this
metabolic pathway generally connote increased granulocyte
production ofreactive oxygen species. However, and somewhat
surprisingly, we could not detect a serotonin-linked increment
in superoxide anion or H202 generation in either unstimulated
or complement-activated. granulocytes (Table 2). Moreover,
serotonin did not provoke detectable release of the granulocyte
lysosomal enzymes, lysozyme, or myeloperoxidase (results not
shown); other granulocyte lysosomal enzymes were not assayed.
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FIG. 1. Specific 51Cr release from
labeled endothelial cells incubated in
the presence of 5 x 106 granulocytes
(PMN} and opsonized zymosan. (Left)
PRP (0.4 ml) enhances endothelial
51Cr leak but not when the serotonin
antagonists methysergide or imipra-
mine were included with the granulo-
cytes and opsonized zymosan. (Right)
Serotonin (5-hydroxytryptamine; 5 fT)
reproduces the platelet-augmenting
effect. The stippled bar represents the
mean and SEM for 51Cr release in-
duced by granulocytes and opsonized
zymosan alone. The PRP or serotonin
(1 pM) wasincubated with imipramine
(1 AM), or methysergide (100 ,uM) for
15 min in the indicated experiments,
and then the granulocytes were added.
This mixture (PMN, platelet release
products, or 5HT, and inhibitors) was
then added to the endothelial cells.
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FIG. 2. Dose-dependent augmentation of granulocyte (PMN)-me-
diated specific 51Cr release from labeled endothelial cells. PMN (5 x
106), opsonized zymosan, and various concentrations of serotonin (5
HT) were incubated with endothelial cells. Each point represents the
mean and standard error of at least three separate triplicate determi-
nations.
DISCUSSION
We have shown that complement-activated granulocytes ad-
here to and damage endothelial cells in vitro (8, 11) and micro-
vasculature in vivo as well (3, 5-7). Other circulating blood cells
also may affect granulocyte-endothelial cell interactions, but
the present in vitro studies suggest that platelets augment this
toxicity through release of their granule constituents, such as
serotonin or one of its metabolites. That other platelet constit-
uents also may interact with granulocytes and render them more
cytotoxic has not been excluded and may be important. For in-
stance, platelets amplify granulocyte adherence to nylon fibers
(23), and others have shown platelet Factor IV can increase the
activity of granulocyte proteases such as elastase (24). More-
over, evidence has been provided that thrombin-stimulated but
not resting platelets (in the presence of endotoxin) enhance
granulocyte adherence to nylon fibers (25), further implicating
constituents ofthe platelet-release reaction in granulocyte func-
tion. Nevertheless, our ability to completely abrogate the plate-
let-augmenting effect on granulocyte-mediated endothelial ra-
diolabel release with two serotonin antagonists, imipramine and
methysergide (Fig. 1), implies that serotonin may well be a
particularly important platelet constituent effecting granulo-
cyte-endothelial interactions.
The mechanism by which added serotonin acts in this regard
is not obvious. Platelets stimulated with opsonized zymosan
released at least 40% of their serotonin for a final concentration
ofbetween 0.05 and 0.2 ,M. Amplified 51Cr release clearly was
achieved at 0.1 ,uM, and while most of our studies were per-
formed at a higher concentration, the dose-response curve pla-
teaus- between 1 and 0.1 ,uM. Serotonin itself is not toxic to
endothelium; it does not alter either spontaneous endothelial
leak of label or that provoked by the oxygen species generated
with xanthine and xanthine oxidase (results not shown): there-
fore, its effects on granulocytes seem more relevant. In this
regard, its capacity to increase the hexose monophosphate-
shunt metabolism- of granulocytes and, by implication, their
production of potentially toxic oxidant compounds is probably
of some importance. We find more compelling, however, the
ability of serotonin to increase granulocyte adherence to target
endothelial cells because, in our previous studies (3, 8, 11),
diverse agents that diminish such adherence, such as cytochal-
asin B. lidocaine, and corticosteroids, decreased PMN-me-
diated endothelial cytotoxicity. How serotonin promotes gran-
ulocyte stickiness is not well defined, but a role for cAMP is not
supported by data so far collected. Although cAMP of granu-
locytes has been found to affect their adhesion to glass and nylon
fibers (26, 27), we have no evidence that altered granulocyte
cAMP underlies serotonin's promotion ofgranulocyte-endothelial
cell adhesion; that is, no detectable change in granulocyte
cAMP levels accompanies serotonin exposure (results not
shown). Conversely, we have gathered preliminary data that
implicate endothelial cell-derived prostacyclin. As shown in
Table 2, serotonin enhances granulocyte adhesion to endo-
thelial cells but not to plastic, implying that endothelial cell
function might be more than passively involved in the cell-cell
interaction. Boxer and his co-workers have reported that pros-
tacyclin decreases granulocyte adhesion to endothelium (28);
therefore, any reduction in this endothelial cell-derived pros-
taglandin might be expected to promote granulocyte adhesion.
In fact, serotonin inhibits by 34% the release ofthe prostacyclin
metabolite 6-keto-prostaglandin F1, from thrombin-stimulated
endothelial cells (16.7 ± 3.7 vs. 25.3 ± 1.2 A.g/Ag of protein)
and by 15% from arachidonate-treated endothelial cells (128.1
+ 9.6 vs. 151.2 ± 7.5 Ag/lg ofprotein). These studies support
a postulated sequence: serotonin released from complement-
stimulated platelets retards endothelial prostacyclin production
Table 2. Effect of serotonin on human granulocytes
Assays of PMN function
monophosphate- PMN adherence, %
PMN medium Superoxide* H202t shunt activityt Plastic Endothelium
HBSS/albumin buffer 3.1 ± 0.7 <0.8 1.0- 53.4 ± 9.3 7.4 ± 4.2
5HT(1 AiM) + buffer 4.2 ± 1.6 <0.8 3.1 ± 0.4 47.1 ± 7.6 17.6 ± 5.8
Activated serum 27.9 ± 0.9 4.9 ± 1.2 6.4 ± 0.6 39.8 ± 6.2 45.0 ± 5.8
Activated serum + 5HT (1 tzM) 25.8 ± 0.4 5.2 ± 1.6 7.0 ± 0.5 41.5 ± 7.0 55.2 ± 8.3
PMN, granulocytes; 5HT, serotonin; HBSS, Hanks' balanced salt solution. The results represent the mean and SEM from
three experiments, each in triplicate. The adherence assay results represent the mean ± SD for at least five experiments, each
in triplicate. Enhanced adherence in the presence of serotonin was significant (P = 0.01) in Student t test.
* Expressed as nanomoles of cytochrome c reduced per 5 x 106 PMN per 15 min.
t Expressed as nanomoles per 1 x 106 PMN per 10 min.
t Hexose monophosphate-shunt activities, measured as 14CO2 release, are expressed as the cpm in stimulated cells divided
by the cpm obtained with the same number of resting neutrophils in parallel flasks. Serum-activated zymosan particles were
prepared as described in Table 1 and were used in metabolic studies; for adherence studies, zymosan-activated serum (15%,
vol/vol) was used instead of opsonized zymosan particles.
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or release; as a result, potentially toxic granulocytes may more
readily adhere to and damage the endothelium.
The temptation to extrapolate these results to situations in
which in vivo vascular injury occurs is tempered by the artifi-
ciality of our in vitro system. The actual meaning of endothelial
51Cr (or ["4C]thymidine) release is not clear. Our previous stud-
ies (8, 11), which used a confirmatory assay of cytotoxicity (that
of fluorochromasia), did support the suggestion that radiolabel
release, at least in part, represents true cytotoxicity. However,
other possibilities such as enhanced endothelial membrane
turnover or nonlethal cellular "leak" are not completely ex-
cluded. In addition, others using similar, but not identical, en-
dothelial cell culture systems have suggested that released gran-
ulocyte proteases may cause endothelial cell detachment from
culture dishes rather than cell death (29). We believe this for-
mulation unlikely in our studies because our assay methods re-
capture detached, intact cells by centrifugation of culture su-
pernates and include their radioactivity with that of the cell
contents. The assay medium contains serum or plasma that in-
hibits endothelial-detaching proteases released by comple-
ment-stimulated granulocytes (29). In fact, only 2-10% of the
cell-associated radioactivity usually detached during the assay.
There was no relationship between cellular detachment and
soluble 51Cr release in the presence or absence of serotonin in
the assay mixture (not shown).
With this caveat, our studies suggest that platelets that be-
come adherent to sites of in vivo endothelial injury might by
their release of serotonin (and other constituents) promote
adhesion of granulocytes to the same or neighboring sites. If
these granulocytes are or subsequently become stimulated, as
by exposure to activated complement, further endothelial in-
jury might supervene. Although this formulation-particularly
the role of serotonin in vascular injury-will need to be vali-
dated by further experiments, it has not escaped our attention
that hyperserotoninemic individuals with the carcinoid syn-
drome develop pulmonary arteriosclerosis in addition to right-
sided endocardial damage. (30, 31).
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